View Older Stories View More Recent Stories
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $352 at Leerink Partners
-
Increasing unusual put option volume: EDR JWN FXY TKO BHC MXEF RCAT URBN NOK ACHR SATS AMGN
-
Oppenheimer Reiterates Outperform Rating on Amgen (AMGN), 'the totality of MariTide's data is still competitive'
-
BTIG Reiterates Viking Therapeutic (VKTX) at Buy, 'continue to see sub-q VK2735 remaining highly competitive'
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Increasing unusual call option volume: KULR RGTI MSTZ NNE QBTS PL DKS SJM VUZI ARQT KODK SIGA SMTC WSM RDW HST AMGN BLBD
-
Morgan Stanley on Amgen (AMGN): 'Initial thoughts on Maritide Ph2 diabesity data'
-
Amgen (AMGN) Falls 8% Following Obesity Data, Rivals Lilly (LLY), Novo Nordisk (NVO) Gain 4%
-
Amgen (AMGN) Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
-
Amgen (AMGN) Appoints Howard Chang as SVP of Research
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Citi Starts Amgen (AMGN) at Neutral
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) Issues Statement on MariTide Phase 1 data
-
Amgen (AMGN) call put ratio 1 call to 1 put after Amgen's AMG-133 Phase 1 bone data
-
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
-
Barclays Reiterates Equalweight Rating on Amgen (AMGN)
-
Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
-
Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data
-
Amgen (AMGN) Quickly Falls to Low, Down Over 4% on Obesity Data Concerns
-
Amgen (AMGN): Tezspire Met Both Co-primary Endpoints In Phase 3 Trial For Chronic Rhinosinusitis With Nasal Polyps
-
Amgen (AMGN) Tops Q3 EPS by 47c; offers guidance
-
Amgen (AMGN) November 1 weekly option implied volatility into quarter results
-
Amgen (AMGN) option IV at high end of range into quarter results
-
Amgen (AMGN) Declares $2.25 Quarterly Dividend; 2.8% Yield
-
Amgen (AMGN) Launches Pavblu As Rival To Regeneron's (REGN) Eylea - Bloomberg
-
Amgen (AMGN) PT Raised to $383 at TD Cowen
-
Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial
-
Truist Securities Downgrades Amgen (AMGN) to Hold
-
Amgen (AMGN) October 350 and 360 calls active as share price down 5.3%
-
Goldman Sachs Reiterates Buy Rating on Immunovant (IMVT)
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Baird Reiterates Underperform Rating on Amgen (AMGN)
-
Truist Securities Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease
-
Amgen (AMGN) To Host Conference Call To Discuss New Topline Data In Inflammation And Rare Disease
-
Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)
-
Amgen (AMGN): Otezla Now Available In The U.S. For Moderate To Severe Pediatric Plaque Psoriasis
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Midday movers: Super Micro Computer, Airbnb and Lyft fall; Shopify rises
-
Amgen (AMGN) PT Raised to $381 at TD Cowen
-
Amgen (AMGN) PT Raised to $362 at RBC Capital
-
Stocks expected to have increasing option volume: AMGN ABNB FTNT SMCI RIVN TOST RDDT WYNN VFC CRUS IAC TRIP
-
Wells Fargo Downgrades Amgen (AMGN) to Equal Weight
-
Amgen (AMGN) Misses Q2 EPS by 1c; updates guidance

